实体器官和造血干细胞移植免疫治疗的进展与挑战
Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation.
作者信息
McDonald-Hyman Cameron, Turka Laurence A, Blazar Bruce R
机构信息
Department of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, MN 55455, USA.
Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02115, USA.Immune Tolerance Network, Massachusetts General Hospital, Boston, MA 02114, USA. Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02115, USA.Immune Tolerance Network, Massachusetts General Hospital, Boston, MA 02114, USA.
出版信息
Sci Transl Med. 2015 Mar 25;7(280):280rv2. doi: 10.1126/scitranslmed.aaa6853.
Abstract
Although major advances have been made in solid organ and hematopoietic stem cell transplantation in the last 50 years, big challenges remain. This review outlines the current immunological limitations for hematopoietic stem cell and solid organ transplantation and discusses new immune-modulating therapies in preclinical development and in clinical trials that may allow these obstacles to be overcome.
摘要
尽管在过去50年里实体器官和造血干细胞移植取得了重大进展，但巨大的挑战依然存在。本综述概述了造血干细胞和实体器官移植目前存在的免疫方面的限制，并讨论了处于临床前开发阶段和临床试验阶段的新型免疫调节疗法，这些疗法可能有助于克服这些障碍。
相似文献
1
Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation.实体器官和造血干细胞移植免疫治疗的进展与挑战
Sci Transl Med. 2015 Mar 25;7(280):280rv2. doi: 10.1126/scitranslmed.aaa6853.
2
Mixed allogeneic chimerism to induce tolerance to solid organ and cellular grafts.混合异基因嵌合体以诱导对实体器官和细胞移植物的耐受。
Acta Haematol. 1999;101(2):78-81. doi: 10.1159/000040928.
3
Hematopoietic stem cells and solid organ transplantation.造血干细胞与实体器官移植。
Transplant Rev (Orlando). 2016 Oct;30(4):227-34. doi: 10.1016/j.trre.2016.07.005. Epub 2016 Aug 3.
4
Harnessing Mechanisms of Immune Tolerance to Improve Outcomes in Solid Organ Transplantation: A Review.利用免疫耐受机制改善实体器官移植的结局：综述。
Front Immunol. 2021 Jun 10;12:688460. doi: 10.3389/fimmu.2021.688460. eCollection 2021.
5
Pharmacologic and immunologic management of cytomegalovirus infection after solid organ and hematopoietic stem cell transplantation.实体器官和造血干细胞移植后巨细胞病毒感染的药物和免疫治疗管理。
Expert Rev Clin Pharmacol. 2018 Aug;11(8):773-788. doi: 10.1080/17512433.2018.1501557. Epub 2018 Jul 26.
6
Toward dual hematopoietic stem-cell transplantation and solid-organ transplantation for sickle-cell disease.针对镰状细胞病的双造血干细胞移植和实体器官移植。
Blood Adv. 2018 Mar 13;2(5):575-585. doi: 10.1182/bloodadvances.2017012500.
7
Pulmonary complications of solid organ and hematopoietic stem cell transplantation.实体器官和造血干细胞移植的肺部并发症
Am J Respir Crit Care Med. 2004 Jul 1;170(1):22-48. doi: 10.1164/rccm.200309-1322SO. Epub 2004 Apr 7.
8
Cell therapy in transplantation: A comprehensive review of the current applications of cell therapy in transplant patients with the focus on Tregs, CAR Tregs, and Mesenchymal stem cells.细胞治疗在移植中的应用：细胞治疗在移植患者中的应用综述，重点关注调节性 T 细胞、嵌合抗原受体调节性 T 细胞和间充质干细胞。
Int Immunopharmacol. 2021 Aug;97:107669. doi: 10.1016/j.intimp.2021.107669. Epub 2021 May 6.
9
Solid organ transplantation following end-organ failure in recipients of hematopoietic stem cell transplantation in children.儿童造血干细胞移植受者终末器官衰竭后的实体器官移植。
Pediatr Nephrol. 2014 Aug;29(8):1337-47. doi: 10.1007/s00467-013-2587-4. Epub 2013 Aug 16.
10
Editorial: "The Role of Immune Checkpoint Molecules in Solid and Hematopoietic Stem Cell Transplantation".社论：“免疫检查点分子在实体器官和造血干细胞移植中的作用”
Front Immunol. 2021 Dec 20;12:822558. doi: 10.3389/fimmu.2021.822558. eCollection 2021.
引用本文的文献
1
Immune isolation-enabled nanoencapsulation of donor T cells: a promising strategy for mitigating GVHD and treating AML in preclinical models.免疫隔离增强供体细胞的纳米囊封：一种有前途的策略，可减轻临床前模型中的 GVHD 并治疗 AML。
J Immunother Cancer. 2024 Sep 5;12(9):e008663. doi: 10.1136/jitc-2023-008663.
2
Cell-free RNA Liquid Biopsy to Monitor Hematopoietic Stem Cell Transplantation.无细胞RNA液体活检用于监测造血干细胞移植
medRxiv. 2024 May 16:2024.05.15.24307448. doi: 10.1101/2024.05.15.24307448.
3
Donor whole blood DNA methylation is not a strong predictor of acute graft host disease in unrelated donor allogeneic haematopoietic cell transplantation.在非亲属供者异基因造血细胞移植中，供者全血DNA甲基化并非急性移植物抗宿主病的有力预测指标。
Front Genet. 2024 Apr 3;15:1242636. doi: 10.3389/fgene.2024.1242636. eCollection 2024.
4
RORγt inverse agonist TF-S14 inhibits Th17 cytokines and prolongs skin allograft survival in sensitized mice.RORγt 反向激动剂 TF-S14 抑制 Th17 细胞因子并延长致敏小鼠皮肤移植物的存活时间。
Commun Biol. 2024 Apr 12;7(1):454. doi: 10.1038/s42003-024-06144-2.
5
A humanized IL-2 mutein expands Tregs and prolongs transplant survival in preclinical models.一种人源化的 IL-2 突变体可扩增 Tregs 并延长临床前模型中的移植存活时间。
J Clin Invest. 2024 Mar 1;134(5):e173107. doi: 10.1172/JCI173107.
6
Complex interactions of cellular players in chronic Graft-versus-Host Disease.慢性移植物抗宿主病中细胞成分的复杂相互作用。
Front Immunol. 2023 Jun 26;14:1199422. doi: 10.3389/fimmu.2023.1199422. eCollection 2023.
7
Development of Cell Therapies for Renal Disease and Regenerative Medicine.细胞治疗在肾脏疾病和再生医学中的发展。
Int J Mol Sci. 2022 Dec 15;23(24):15943. doi: 10.3390/ijms232415943.
8
Engineering of hybrid spheroids of mesenchymal stem cells and drug depots for immunomodulating effect in islet xenotransplantation.工程化间充质干细胞-药物微球用于胰岛异种移植的免疫调节作用。
Sci Adv. 2022 Aug 26;8(34):eabn8614. doi: 10.1126/sciadv.abn8614. Epub 2022 Aug 24.
9
Donor Macrophages Modulate Rejection After Heart Transplantation.供体巨噬细胞调节心脏移植后的排斥反应。
Circulation. 2022 Aug 23;146(8):623-638. doi: 10.1161/CIRCULATIONAHA.121.057400. Epub 2022 Jul 26.
10
mTORC1 Inhibition Protects Human Regulatory T Cells From Granzyme-B-Induced Apoptosis.mTORC1 抑制可保护人调节性 T 细胞免受颗粒酶-B 诱导的凋亡。
Front Immunol. 2022 Jun 10;13:899975. doi: 10.3389/fimmu.2022.899975. eCollection 2022.
本文引用的文献
1
A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study.基于生物标志物的急性移植物抗宿主病预后评分：一项多中心研究
Lancet Haematol. 2015 Jan;2(1):e21-9. doi: 10.1016/S2352-3026(14)00035-0. Epub 2014 Dec 23.
2
The chromatin-modifying enzyme Ezh2 is critical for the maintenance of regulatory T cell identity after activation.染色质修饰酶Ezh2对激活后调节性T细胞身份的维持至关重要。
Immunity. 2015 Feb 17;42(2):227-238. doi: 10.1016/j.immuni.2015.01.007. Epub 2015 Feb 10.
3
Blockade of CD40-CD154 costimulatory pathway promotes long-term survival of full-thickness porcine corneal grafts in nonhuman primates: clinically applicable xenocorneal transplantation.阻断CD40-CD154共刺激通路可促进猪全层角膜移植片在非人灵长类动物中的长期存活：临床适用的异种角膜移植。
Am J Transplant. 2015 Mar;15(3):628-41. doi: 10.1111/ajt.13057. Epub 2015 Feb 12.
4
IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future.白细胞介素 6 抑制剂治疗类风湿关节炎：过去、现在和未来。
Arch Pharm Res. 2015;38(5):575-84. doi: 10.1007/s12272-015-0569-8. Epub 2015 Feb 4.
5
Tracking donor-reactive T cells: Evidence for clonal deletion in tolerant kidney transplant patients.追踪供体反应性T细胞：耐受肾移植患者中克隆清除的证据。
Sci Transl Med. 2015 Jan 28;7(272):272ra10. doi: 10.1126/scitranslmed.3010760.
6
Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial.异体造血干细胞移植后加用托珠单抗抑制白细胞介素-6 预防移植物抗宿主病：一项 1/2 期试验。
Lancet Oncol. 2014 Dec;15(13):1451-1459. doi: 10.1016/S1470-2045(14)71017-4. Epub 2014 Nov 14.
7
Histone deacetylase inhibition regulates inflammation and enhances Tregs after allogeneic hematopoietic cell transplantation in humans.组蛋白去乙酰化酶抑制作用可调节炎症，并在人类异基因造血细胞移植后增强调节性T细胞。
Blood. 2015 Jan 29;125(5):815-9. doi: 10.1182/blood-2014-10-605238. Epub 2014 Nov 26.
8
The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis.Rho激酶：多种促纤维化过程的关键介质及肺纤维化新疗法的合理靶点。
Pharmacol Rev. 2015;67(1):103-17. doi: 10.1124/pr.114.009381.
9
Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism.选择性口服ROCK2抑制剂通过STAT3依赖性机制下调人T细胞中IL-21和IL-17的分泌。
Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):16814-9. doi: 10.1073/pnas.1414189111. Epub 2014 Nov 10.
10
Vascular endothelium as a target of immune response in renal transplant rejection.血管内皮作为肾移植排斥反应中免疫反应的靶点。
Front Immunol. 2014 Oct 21;5:505. doi: 10.3389/fimmu.2014.00505. eCollection 2014.
Zotero 插件